Skybiotech Healthcare (512036)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹145 |
| Market Cap | ₹29.23 Cr |
| P/E Ratio | 0 |
| ROCE | 0% |
| ROE | -2.33% |
| Dividend Yield | 0% |
| Profit Growth | -23.08% |
| Debt/Equity | — |
| Sales Growth | -61.9% |
| 52-Week Range | ₹116.45 — ₹207.85 |
| Sector | Textiles & Apparels |
| Book Value | ₹49.63 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Reading Skybiotech's numbers, I am reminded of my rule: if you can't understand it, don't invest. Here, even the basics are worrying. This textile company reported sales of just ₹1 Cr in the latest quarter, down 61.90% from the prior year. A firm cannot build a moat on collapsing revenue. Profit is negative, albeit only around ₹0 Cr, which tells me the business is not in a catastrophic cash burn, but it is also not earning a rupee of return on equity. ROE is -2.33%, ROCE is 0.00%, and the Piotroski F-Score is a dreadful 2 out of 9. These are not the fingerprints of a franchise; they are the fingerprints of a business struggling to stay relevant.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer